Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 28, 2023 07:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor...
August 10, 2023 07:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson’s...
August 07, 2023 07:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®

BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and development of the next generation of allosteric small...
July 31, 2023 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference

BETHESDA, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small...
June 01, 2023 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Present at the Jefferies Healthcare Conference

BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small...
May 12, 2023 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for start of Phase 1 clinical trial of GT-02287 to the...
May 03, 2023 09:15 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease

BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today...
April 12, 2023 16:30 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small...
March 29, 2023 08:52 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

BETHESDA, Md., March 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small...
March 23, 2023 16:05 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

Company expects completion of IND-enabling studies of GT-02287 in H1 2023Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease expected by mid-year 2023$22.1...